Business Wire
-
Edgewise Receives U.S. FDA Fast Track Designation For EDG-5506 For The Treatment Of Duchenne Muscular Dystrophy (Duchenne)
2/13/2024
Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
-
VantAI Enters Collaboration With Bristol Myers Squibb To Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
2/13/2024
VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
-
HTuO Biosciences Joins Johnson & Johnson Innovation - JLABS
2/12/2024
HTuO Biosciences, a biotechnology company developing an innovative molecular simulation platform for drug discovery, announces it has joined Johnson & Johnson Innovation - JLABS as a resident virtual company.
-
Iambic Therapeutics Announces New Research Published In Nature Machine Intelligence Demonstrating The Capabilities Of Its Generative AI Neuralplexer Technology To Predict Protein-Ligand Complex Structures
2/12/2024
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, today announced the publication of research in Nature Machine Intelligence showing that its NeuralPLexer technology outperforms other state-of-the art systems in predicting the structure of protein-ligand complexes as well as the conformational changes to these structures from the addition of drug molecules.
-
Encoded Therapeutics Announces US IND Clearance And Australian CTA Approval For Dravet Syndrome Gene Therapy Candidate ETX101
2/6/2024
Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today outlined the global development strategy for its lead gene therapy candidate, ETX101, for the treatment of SCN1A+ Dravet syndrome. Individuals with Dravet syndrome, the most common developmental and epileptic encephalopathy, experience a spectrum of clinical symptoms, including treatment-resistant seizures and neurodevelopmental stagnation.
-
Bruker Introduces The Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System For Drug Discovery At SLAS2024
2/5/2024
At the SLAS2024 International Conference and Exhibition, Bruker Corporation today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.
-
SCIEX Expands High-Throughput Screening Solutions With Echo MS+ System
2/2/2024
SCIEX, a global leader in life science analytical technologies, launches the Echo MS+ system at SLAS 2024.
-
Inoviv Secures Investment To Expand Quantitative Proteomics Product Offerings To Accelerate Drug Development Pipelines
1/30/2024
Biomarker pioneer Inoviv has secured significant funding from venture capital firm Hoxton Ventures and leading investment manager Foresight Group to expand the delivery of highly accurate, fully quantitative targeted biomarker workflows and panels.
-
Opentrons Launches Automation Marketplace To Expand Lab Robotics Accessibility And Streamline Drug Discovery And Microbiome Research
1/30/2024
Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics, today announced the launch of its automation marketplace, with tools and software from Opentrons’ partners that can be easily integrated into Opentrons robotics systems, catering to rapidly expanding sectors like drug discovery and microbiome research.
-
Ceremorphic Announces New Life Sciences Division With New Design Methodology Based On Its Proprietary Analog And AI Technology That Can Significantly Reduce R&D Costs
10/24/2023
Ceremorphic, a fabless silicon and system development company, today announced the formation of a new life sciences division called “Ceremorphic Life Sciences,” which has been established to transform the entire drug discovery and development process.